ArticleFrontiers in immunology2026
Relapse predictors and brain atrophy in antibody-positive and antibody-negative autoimmune encephalitis: a multicenter cohort study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Autoimmune encephalitis (AE) is clinically heterogeneous, but whether relapse predictors and structural correlates of disability differ by antibody status remains unclear. We aimed to identify serostatus-specific predictors of relapse and determine whether brain atrophy is associated with 12-month functional outcome across the AE spectrum. Methods: In an 11-center retrospective cohort study conducted from 2016 to 2024, we included patients fulfilling 2016 AE diagnostic criteria with ≥12 months of follow-up. Serostatus, relapse, 12-month modified Rankin Scale (mRS), and MRI-defined diffuse cortical atrophy (DCA), medial temporal atrophy (mTA), and cerebellar atrophy were analyzed. Multivariable logistic regression was used to identify relapse predictors within serostatus strata. Functional outcomes and regional brain atrophy patterns were compared between antibody-positive and antibody-negative cohorts. Results: Among 467 patients (361 antibody-positive, 106 antibody-negative), 1-year relapse rates were 25.5% and 22.6%, respectively. In antibody-positive AE, faciobrachial dystonic seizures were independently associated with relapse (OR = 2.50, Conclusions: Relapse-associated factors differed between antibody-positive and antibody-negative AE. In both cohorts, moderate-to-severe DCA and mTA were associated with greater disability at 12 months. Structural MRI may therefore provide complementary information for prognostic assessment, pending prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.